33 results on '"Patel, Juber"'
Search Results
2. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
3. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
4. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients
5. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
6. Resistance to TRK inhibition mediated by convergent MAPK pathway activation
7. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study
8. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations
9. Abstract 4284: Enhancing subclonal reconstruction algorithm for resolving complex tumor phylogenies from multi-sample tumor DNA sequencing
10. Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models
11. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer
12. Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers
13. Abstract 5688: RNA-mediated DNA repair: A novel repair pathway in homologous recombination-deficient cancers
14. Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications
15. Cell-free DNA analysis as a molecular tool to monitor response to immune checkpoint inhibition in endometrial cancer.
16. HER kinase inhibition in patients with HER2- and HER3-mutant cancers
17. Additional file 2 of Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients
18. Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay
19. Cell‐free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience
20. Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay
21. Abstract PR07: MSI detection in plasma cfDNA: MSI as a marker of disease burden
22. Abstract PR08: Validation and clinical implementation of MSK-ACCESS, an ultra-deep sequencing assay for noninvasive somatic mutation profiling
23. Abstract 2516: A bioinformatics framework for high-sensitivity detection and monitoring of oncogenic gene fusions in plasma cfDNA
24. Abstract 1387: Tracking minimal residual disease in post-operative cell-free DNA using MSK-ACCESS
25. Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.
26. Abstract 3656: Detecting MSI in plasma: Implications for early detection of lynch associated tumors
27. Abstract 5598: Development and optimization of a comprehensive high-sensitivity NGS cancer assay and bioinformatics pipeline for plasma cfDNA profiling
28. Gut microbiomes of wild great apes fluctuate seasonally in response to diet
29. Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas
30. Abstract CT001: Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study
31. Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363).
32. APOBEC3 mutagenesis drives therapy resistance in breast cancer.
33. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.